Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 31.09% is in line with its 5-year average of 32.34%, around the middle of its 5-year range (19.33%–37.70%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.94% below its 12-month average of 33.41%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
31.09%
EBITDA MARGIN AVG TTM
33.41%
EBITDA MARGIN AVG 3Y
31.01%
EBITDA MARGIN AVG 5Y
32.34%
EBITDA MARGIN AVG 10Y
36.03%
EBITDA MARGIN AVG 15Y
37.08%
EBITDA MARGIN AVG 20Y
36.40%
CURRENT VS TTM AVG
-6.94%
CURRENT VS 3Y AVG
+0.27%
CURRENT VS 5Y AVG
-3.87%
CURRENT VS 10Y AVG
-13.69%
CURRENT VS 15Y AVG
-16.14%
CURRENT VS 20Y AVG
-14.57%
Roche Holding AG
Market Cap
$359.46B
EBITDA Margin
31.09%
TTM Avg
33.41%
3Y Avg
31.01%
5Y Avg
32.34%
Market Cap
$358.76B
EBITDA Margin
5.21%
TTM Avg
7.15%
3Y Avg
8.47%
5Y Avg
8.86%
Market Cap
$369.34B
EBITDA Margin
45.17%
TTM Avg
41.84%
3Y Avg
33.12%
5Y Avg
31.32%
Market Cap
$255.15B
EBITDA Margin
33.16%
TTM Avg
30.52%
3Y Avg
27.50%
5Y Avg
25.68%
Market Cap
$234.38B
EBITDA Margin
24.44%
TTM Avg
24.78%
3Y Avg
25.35%
5Y Avg
27.67%
Market Cap
$205.42B
EBITDA Margin
48.42%
TTM Avg
49.59%
3Y Avg
48.46%
5Y Avg
47.82%
Market Cap
$193.04B
EBITDA Margin
24.35%
TTM Avg
24.15%
3Y Avg
24.77%
5Y Avg
25.59%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 31.09% | 33.41% | 31.01% | 32.34% |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 5.21% | 7.15% | 8.47% | 8.86% |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 45.17% | 41.84% | 33.12% | 31.32% |
| AbbVie Inc. (ABBV)vs › | $455.87B | 46.16% | 38.63% | 40.64% | 41.43% |
| AstraZeneca PLC (AZN)vs › | $255.15B | 33.16% | 30.52% | 27.50% | 25.68% |
| Amgen Inc. (AMGN)vs › | $235.85B | 43.12% | 40.78% | 43.34% | 44.32% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 24.44% | 24.78% | 25.35% | 27.67% |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 48.42% | 49.59% | 48.46% | 47.82% |
| Abbott Laboratories (ABT)vs › | $193.04B | 24.35% | 24.15% | 24.77% | 25.59% |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | 49.12% | 32.26% | 34.27% | 33.90% |
Gross Margin
73.7%
EBITDA Margin
31.1%
Operating Margin
29.2%
Net Margin
20.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 31.09% |
| 2025-12-31 | 31.87% |
| 2025-06-30 | 37.28% |
| 2024-12-31 | 19.33% |
| 2024-06-30 | 34.87% |
| 2023-12-31 | 24.99% |
| 2023-06-30 | 37.63% |
| 2022-12-31 | 31.70% |
| 2022-06-30 | 37.70% |
| 2021-12-31 | 31.88% |
| 2021-06-30 | 37.44% |
| 2020-12-31 | 35.30% |
| 2020-06-30 | 41.12% |
| 2019-12-31 | 34.79% |
| 2019-06-30 | 42.52% |
| 2018-12-31 | 34.30% |
| 2018-06-30 | 41.40% |
| 2017-12-31 | 34.42% |
| 2017-06-30 | 41.68% |
| 2016-12-31 | 38.14% |
| 2016-06-30 | 40.39% |
| 2015-12-31 | 35.74% |
| 2015-06-30 | 39.91% |
| 2014-12-31 | 35.41% |
| 2014-06-30 | 41.47% |
| 2013-12-31 | 36.89% |
| 2013-06-30 | 41.25% |
| 2012-12-31 | 38.67% |
| 2012-06-30 | 36.29% |
| 2011-12-31 | 36.29% |
| 2011-06-30 | 37.76% |
| 2010-12-31 | 37.76% |
| 2010-06-30 | 33.90% |
| 2009-12-31 | 33.90% |
| 2009-06-30 | 29.84% |
| 2008-12-31 | 39.44% |
| 2008-06-30 | 33.20% |
| 2007-12-31 | 33.20% |
| 2007-06-30 | 35.65% |
| 2006-12-31 | 33.94% |
| 2006-06-30 | 33.46% |
| 2005-12-31 | 26.46% |
| 2005-06-30 | 28.06% |
| 2005-01-31 | 28.06% |
| 2004-06-30 | 33.87% |
| 2003-12-31 | 26.20% |
| 2003-06-30 | 19.30% |
| 2002-12-31 | 24.82% |
| 2002-06-30 | -5.61% |
| 2001-12-31 | 11.36% |
| 2001-06-30 | 21.56% |
| 2000-12-31 | 21.59% |
| 2000-06-30 | 48.02% |
| 1999-12-31 | 27.67% |
| 1999-06-30 | 36.71% |
| 1999-01-31 | 36.71% |
| 1998-06-30 | 30.13% |
| 1998-01-31 | 30.13% |
